Sana Biotechnology joins the Board of Directors.

All news Company news

Link copied

12:05 | 2 February 2021

Sana Biotechnology joins the Board of Directors.

About company

Sana Biotechnolo was founded in 2018, is headquartered in Seattle, and employs about 240 people. Sana Biotechnology was founded on the belief that artificially created cells will be one of the most important transformations in medicine in the next few decades. The burden of disease, the root cause of which can be eliminated with artificially created cells, is great. Sana Biotechnology’s long-term ambition is to be able to control or modify any gene in the body, replace any damaged or missing cell and markedly improve access to cellular and gene-based medicines. Sana Biotechnology has assembled a group of experienced scientists, engineers and company builders and combined them with the necessary technology to advance this vision. Sana Biotechnology is developing in vivo and ex vivo cell engineering platforms that are revolutionizing treatments in a wide range of therapeutic areas with unmet treatment needs, including cancer, diabetes, central nervous system (CNS) disorders, cardiovascular disease and genetic disorders, among others. While the current products are all in preclinical development, Sana Biotechnology’s goal is to submit several new investigational drug applications in both 2022 and 2023.

More about the board of directors

Company, announced the appointment of Josh Bilenker, MD, Alice Racine, MD, and Michelle Seitz, CFA, to the Sana’a Board of Directors.

“Josh, Alice and Michelle share a passion and commitment to our long-term vision of engineering cells to create medicines that improve patients’ lives. The diversity of their experience and expertise will be critical to our strategy, decision making, risk management and leadership. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and ensuring broad patient access to our therapies. We bring together more than 250 people to build a solid company that is changing the way the world treats disease. Sana Biotechnology operates in Seattle, Cambridge and South San Francisco”
— said the company’s president and chief executive officer Steve Harr

ABOUT THE IPO

IPO date: 03.02.2021

Bidding start date: 04.02.2021

Income forecast: +28%

Placement range: $20 – 23

Exchange: NASDAQ

Ticker: SANA

Plans to raise: $322 million

Underwriters: Morgan Stanley / Goldman Sachs / JP Morgan / BofA Securities

Follow the information in a format that is convenient for you: Telegram, Facebook, YouTube.

Uncategorized

19:11 | Apr 05, 2024

Toncoin enters top 10 crypto by market capitalization, overtakes Avalanche

Toncoin, The Open Network’s native cryptocurrency token, has once again entered the list of the 10 most significant coins by […]

Uncategorized

16:21 | Mar 04, 2024

Bitcoin Tops $65K as Bullish Bets Climb to Record High

The largest cryptocurrency is now just 5% away from its 2021 high in U.S. dollar terms, having already reached records […]

Hereby "Global Venture Partners s.r.o." notifies that it carries out its activities in accordance with paragraph 1 of article 15, the law on investment companies and investment funds of 19.06.2019. Listed in the ZISIF § 15 para. 1 asset management list managed by the CNB in accordance with § 596 (1) CRR. (F) ZISIF.

IČO: 08241473. LEI: 5493003MKEWYLZ837883...
This information on the site is not an individual investment recommendation, and the financial instruments or transactions mentioned in this material may not correspond to your investment profile, financial situation, investment experience, investment goals. Determining the compliance of a financial instrument or transaction with investment objectives, investment horizon and risk tolerance is the task of the investor
Venture fund Global Venture Partners s.r.o. is not responsible for possible losses of the investor in case of investing in the financial instruments mentioned in this material and does not recommend using the specified information as the only source of information when making an investment decision.
* The Venture Fund does not provide guarantees regarding the reliability and accuracy of the information provided, none of the assumptions contained in this material can be interpreted as a guarantee of investment reliability, income stability and possible benefits associated with management methods or the choice of specific financial instruments. The value of investment products may increase and decrease, the results of investing in the past do not determine future income, the company does not guarantee the profitability of investments in investment funds. All information about the profitability (value gain) of the product managed by Global Venture Partners s.r.o. are quoted excluding commissions and taxes. Charging a commission will reduce the return on investment in investment products. Before purchasing an investment product, you should carefully read the rules of trust management for this product. Services for transactions with foreign securities are available to persons who are qualified investors in accordance with applicable law and are performed in accordance with the restrictions established by applicable law.

Show

Hide